Proliferative diabetic retinopathy (PDR) is an advanced stage of diabetic eye disease characterized by the growth of abnormal blood vessels in the retina. According to Temesgen Gebeyehu Wondmeneh et al., 2024, it is the leading cause of blindness among working-age individuals in industrialized regions. As of 2010, over 100 million people were affected globally, with projections indicating over 190 million cases by 2030. According to the proliferative diabetic retinopathy pipeline analysis by Expert Market Research, therapies like Faricimab are gaining prominence. The growing focus on targeted biologics and early diagnosis is expected to drive market growth in the coming years.
Major companies involved in the proliferative diabetic retinopathy pipeline analysis include Valo Health, Inc., Shanghai Refreshgene Technology Co., Ltd., and others.
Leading drugs currently in the pipeline include BI 764524, RRG001, and others.
Rising prevalence of diabetes, increased clinical trial activity, and advancements in anti-VEGF and gene therapies are driving significant pipeline expansion for proliferative diabetic retinopathy drug development.
The Proliferative Diabetic Retinopathy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into proliferative diabetic retinopathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for proliferative diabetic retinopathy. The proliferative diabetic retinopathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The proliferative diabetic retinopathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with proliferative diabetic retinopathy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to proliferative diabetic retinopathy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Proliferative diabetic retinopathy (PDR) is an advanced stage of diabetic retinopathy that occurs when abnormal new blood vessels form on the retina due to prolonged high blood sugar levels damaging retinal blood vessels. These fragile vessels can leak blood into the vitreous, leading to vision impairment or blindness. Without timely intervention, PDR may result in permanent vision loss.
Proliferative diabetic retinopathy treatment includes anti-vascular endothelial growth factor (VEGF) injections, laser photocoagulation, and surgical vitrectomy to reduce leakage, prevent new vessel growth, and preserve vision. In May 2025, Roche’s Susvimo received FDA approval for treating diabetic retinopathy. The implant provides continuous ranibizumab delivery, reducing treatment frequency to one refill every nine months, offering patients a more durable and effective option.
The growing global burden of diabetes has led to a sharp increase in proliferative diabetic retinopathy (PDR), a leading cause of preventable blindness. As diabetes incidence rises, so does the prevalence of associated retinal complications, particularly in low- and middle-income countries. According to Temesgen Gebeyehu Wondmeneh et al., 2024, the global prevalence of diabetic retinopathy was 25.2%, and it affected over 100 million people in 2010, with projections exceeding 190 million by 2030. Prevalence rates are highest in Africa (35.9%) and the Western Pacific (36.2%), while Sub-Saharan Africa is expected to have 47.1 million diabetes cases by 2045. An estimated 10% of diabetic individuals in this region are affected by vision-threatening retinopathy.
This section of the report covers the analysis of proliferative diabetic retinopathy drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The proliferative diabetic retinopathy pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total proliferative diabetic retinopathy clinical trials at 33%. This reflects a strong focus on mid-stage clinical development. Phase II is followed by phase III at 27%, and phase IV at 20%. The robust pipeline across all phases indicates promising advancements, supporting future growth in the proliferative diabetic retinopathy market.
The drug molecule categories covered under the proliferative diabetic retinopathy pipeline analysis include small molecule, polymer, peptide, monoclonal antibody, and gene therapy. The proliferative diabetic retinopathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for proliferative diabetic retinopathy. Anti-VEGF therapies remain the cornerstone of treatment in the proliferative diabetic retinopathy drug pipeline. For instance, tarcocimab tedromer, an anti-VEGF antibody biopolymer conjugate, is under phase 3 investigation for improving diabetic retinopathy severity scores. Additionally, agents such as RC28-E and OPT-302 are being evaluated for their dual-targeting properties, offering potential advantages in treatment-resistant cases.
The EMR report for the proliferative diabetic retinopathy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed proliferative diabetic retinopathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in proliferative diabetic retinopathy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for proliferative diabetic retinopathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of proliferative diabetic retinopathy drug candidates.
BI 764524, sponsored by Boehringer Ingelheim, is currently under evaluation in the HORNBILL Phase I/IIa study for proliferative diabetic retinopathy with diabetic macular ischemia. The study is examining the safety, tolerability, and early biological effects of BI 764524, a novel intravitreal agent designed to neutralize Sema3A. The drug is being administered to patients previously treated with panretinal photocoagulation.
RRG001, sponsored by Li Xiaorong of Tianjin Medical University Eye Hospital, is currently being evaluated in an early Phase 1 study. The objective is to assess the preliminary safety and efficacy of a single subretinal injection of this gene therapy after vitrectomy in patients with Proliferative Diabetic Retinopathy (PDR). RRG001 aims to reduce complications and slow disease progression.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Proliferative Diabetic Retinopathy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for proliferative diabetic retinopathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into proliferative diabetic retinopathy collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share